Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN2312 in advanced breast cancer
NCT06638307Phase 1Recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1 trial of MEN2312 in breast cancer (2 arms), sponsored by Stemline Therapeutics. Primary endpoints: Dose-limiting Toxicity at Day 28 and Recommended Phase 2 Dose at Month 6. Started Oct 2024; status: recruiting.
02
Drugs
MEN2312
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06638307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06638307.